Xarelto Lawsuit Alleges Studies On Blood Thinner Were Not Reliable Or Properly Managed

December 17, 2015 – – BloodThinnerHelp.com reports on a lawsuit filed against the manufacturers of blood-thinning drug Xarelto, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The lawsuit alleges that the companies neglected to properly warn consumers of the significant bleeding issues associated with their drug, and also that the studies that medical journals and advertisements relied on were unreliable and improperly managed. The lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-04273.

Upon its initial market release, Xarelto was considered a revolutionary new type of blood thinner. Unlike warfarin, which has been around for decades, it promised no blood or diet monitoring. Plaintiffs involved in lawsuits against the drug today, however, are no longer focused on these benefits. A glaring negative is what they instead see: Xarelto has no available antidote. So while the effects of warfarin can be quickly reversed by applying vitamin K to someone who is bleeding, the effects of Xarelto cannot. This could be the difference between life and death for those with internal or external bleeding episodes.

Patients who use Xarelto and begin to bleed are at risk for uncontrollable bleeding. To treat individuals in these circumstances, physicians have to resort to extreme life saving measures such as blood transfusions, or surgery to remove pressure and pooling blood. In court documents, plaintiffs have stated: “Importantly, Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its effects.”

Generally, consumers are prescribed Xarelto to treat atrial fibrillation, pulmonary embolism, or deep vein thrombosis. The drug can also be given to those who have undergone recent hip or knee replacement surgeries. In these patients, it is intended to help prevent the risk blood clots and stroke. It has been noted that in medical journals across the country, Xarelto is the most widely advertised drug. These journals are meant to keep the medical community aware of current medical trends and advancements.

The plaintiffs in this particular case accuse the defendants of focusing only on the positive aspects of the drug in both advertisements and studies noted to the public. What they conceal, these plaintiffs allege, is the great dangers the drug poses, including death by bleeding out. Several plaintiffs involved in the currently consolidated Xarelto lawsuits are representing individuals who have died from severe bleeding episodes while taking the drug. In this complaint, plaintiffs make note that throughout both the U.S. and Germany, there have been thousands of “adverse events” reported which are linked to Xarelto use.

The Xarelto bleeding lawsuit cases now number over 2,200 in federal court. They have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation in MDL number 2592, and are being overseen in the Eastern District of Louisiana by the Honorable Judge Eldon Fallon. As these lawsuits await trial preparations, they are expected to continue to grow in number.

Attorney Joseph Osborne is working to ensure that everyone negatively affected by Xarelto will have the opportunity to explore their legal rights. These individuals may be entitled to significant compensation. Patients who have used Xarelto and subsequently suffered from adverse health effects are being offered complimentary legal consultations at this time.

To ask questions or request more information on this topic, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60006458